As "energy dominance" replaces "energy transition" as the animating theme of energy policy around the globe, the life sciences and health care sector faces a rapidly evolving regulatory landscape that is reshaping operational and strategic priorities. Faced with the challenge of providing stable and adequate energy supplies amid the growing demands of the digital age (e.g., the rise of AI and cryptocurrency), nations are increasingly looking to traditional as well as low and zero carbon energy sources. At the same time, new EU legislation and global standards are setting the pace for change and a continued focus on sustainability.

1. Regulatory drivers and compliance

2026 will be pivotal, with the EU's Corporate Sustainability Reporting Directive (CSRD) and Green Deal requiring life sciences companies to report on emissions, energy use, and sustainability performance. The revised EU pharmaceutical legislation ("pharma package") and the Critical Medicines Act introduce stricter obligations for medicine availability, supply chain resilience, and environmental standards. These reforms demand robust compliance programs, as non-compliance can result in fines, litigation, and reputational harm.

2. Operational impacts and supply chain transformation

As aging electric grids are strained by burgeoning demand for electricity, health care facilities and laboratories are taking steps to improve energy efficiency, invest in energy-efficient equipment and pursue other innovative solutions such as embedded generation and microgrids.

The Packaging and Packaging Waste Regulation (PPWR), effective from August 2026, mandates recyclable packaging and the minimization of hazardous substances, directly impacting medical device and pharmaceutical supply chains. Companies must redesign packaging, adapt procurement strategies, and ensure traceability of sustainable materials.

Supply chain due diligence is further reinforced by the Critical Medicines Act, which requires mapping and securing the supply of essential ingredients and products. The demand for sustainable chemicals and green manufacturing processes is rising, prompting innovation and collaboration across the sector.

3. Risk management and strategic planning

Transitioning to any new sources of power generation or energy involves upfront investment and complex risk management. The revised Product Liability Directive (PLD) expands liability for products, including software and AI-driven medical devices, and lowers the evidentiary burden for claimants. This increases the importance of transparent reporting, robust governance, and proactive legal review of sustainability claims to avoid greenwashing allegations.

Shaping the future

Energy concerns are now integral to the future of life sciences and health care. By embracing sustainable practices, investing in innovation, and staying ahead of regulatory trends, organizations can not only achieve long-term resilience and efficiency but also position themselves as leaders in a rapidly evolving economy. Proactive adaptation today will define the sector's success and competitiveness in the years to come.